Please assess the completion status of the following clinical trial:

Trial Title: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects at least 18 years of age with center-involved macular edema secondary to CRVO with mean central retinal thickness ≥ 250 μm on OCT~* ETDRS best corrected visual acuity of 20/40 to 20/320 (73 to 24 letters) in the study eye~Exclusion Criteria:~* Previous treatment with anti-angiogenic drugs in the study eye (Pegaptanib sodium,anecortave acetate, bevacizumab, ranibizumab, etc.)~* Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye~* CRVO disease duration \> 9 months from date of diagnosis~* Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1~* Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VEGF Trap-Eye (Type: EXPERIMENTAL): Monthly IVT injection of VEGF Trap-Eye 2.0 mg until Week 24 Primary Endpoint
- Sham (Type: SHAM_COMPARATOR): Monthly Sham IVT injection until Week 24 Primary Endpoint

Based on this trial design, predict the completion outcome and termination type (if applicable).